How should we choose some new crown vaccines in our country in the future?

An
and Consino Bio-developed vaccine in phase III clinical trials in the middle of the analysis showed that after 28 days of single-shot vaccination, the vaccine on the protection efficiency of severe neo-crown pneumonia 100%, the overall protection efficiency of 74.8%, no serious adverse vaccine-related reactions. What does it mean to be the first vaccine to enter clinical trials in China? "News 1 and 1" Bai Yansong wire China CDC researcher, WHO vaccine research and development
consultant Yan Yiming, common concern.chen Wei
team's vaccine is a single shot, has a huge advantage. So does double injection have its other advantages?
China CDC researcher, WHO vaccine research and development
will be consultant Yan Yiming: everything is beneficial, double-injection vaccination although the immunization cycle is a little longer, may ensure that the two-shot vaccination rate to decline, but it induces the intensity of the immune response, can predict its future durability, so it has its advantages and disadvantages.chen Wei
team's vaccine was the first to come to the fore and the first to begin clinical trials. But when I heard this news today, many people's first reaction will be that both The National Drug and Koxing have been vaccinated for so long, why is Chen Wei
s vaccine "slow"?
, a researcher at the China Center for Disease Control and Prevention and a consultant to WHO's Vaccine Research and Development
Conference, Said: Not only in our country, but also in our country, the global vaccine is progressing at an extraordinary rate. So the so-called "slow", the main reason is that the domestic outbreak control is too good, we can only in the risk-free population, there is no virus attack in the country in the case of phase one or two clinical trials. But to phase three, there must be a high rate of new infections, there must be a large number of cases, in order to test the vaccine's protection against disease. We no longer have this condition in our country, we can only go abroad to carry out Phase III clinical trials. It depends on the countries we work with, the institutions we work with, the efficiency between them and the conditions between them, so some countries may not have the highest incidence rates, such as Europe and the United States, where the incidence is particularly high and progress can be made quickly. So in this case we are limited by people.many countries do not have a vaccine, need to import a lot, our country already has several vaccines, then how to choose?
: This is a very important issue, not only for national policy makers, but also for the public to participate in vaccination, and it is a critical issue, " said Yiming Yan, a researcher at the China Center for Disease Control and Prevention and a consultant to the WHO Vaccine Research and Development
Association. Although there are five technical routes in our country, each vaccine is not the same in terms of effectiveness, safety and accessability. In terms of protective effect, the latest mRNA vaccine has more than 90% protection effect, inactivated vaccine and virus vector vaccine in the range of 70% to 80%. In terms of safety, medicine is an experimental science, only through the test, then its safety, the size of the degree of certainty, depending on how many people were tested, how long the test. Inactivated vaccines have been used by humans for hundreds of years, and have been used by the entire planet, so its safety and confidence in it are the highest.several vaccines in China are stored and transported in an environment of minus 2-8 degrees, but the U.S. is more than 90 percent efficient and requires minus 60 to 70 degrees, which most countries can't. And China's vaccine research and development from the beginning chose to be pragmatic, which is also for developing countries to consider.
China CDC researcher, WHO vaccine research and development
will be consultant Yan Yiming: China's vaccine access, storage, transportation environment are 2-8 degrees, and many of our enterprises have done accelerated testing, even if 37 degrees to save a few weeks of time is no problem, so in transport, even if the transport conditions are worse, our vaccine is able to ensure quality and effectiveness. In this sense, temperature conditions that require minus 70 degrees or minus 20 to 30 degrees are not suitable for use in developing countries, and even in some economically backward areas of developed countries, it is difficult to vaccinate large-scale populations. In addition, china's vaccine access to the international community by so many developing countries, in addition to the resilience of the vaccine itself science and technology, but also with the construction of our human destiny community and China's vaccine is a public
concept, so our support for developing countries, with our national concept is basically synchronized.